Fenwick & West LLP
Lasofoxifene treatment of breast cancer
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
Duke University
A A A C A C A A A C A A A A C
A61P A61K A61P C12Q A61K C12Q A61K A61K A61K C12Q A61K A61K A61P A61K C12Q
inventional inventional inventional inventional inventional additional inventional inventional inventional additional inventional inventional inventional inventional inventional
Stephanie L. Ching-yi Donald P. Kaitlyn
Gaillard Chang McDonnell Andreano